Amgen (NQ:AMGN)

Biogen gains exclusive rights to Vanqua's oral C5aR1 antagonist, boosting its immunology pipeline with potential across multiple immune diseases.

Topics Artificial Intelligence

Biogen's Immunology Pipeline Has Long-Term Potential: Analyst ↗

October 24, 2025

Via Benzinga

1 Top Dividend Growth Stock to Buy Right Now ↗

October 24, 2025

Its shares might not remain undervalued for that much longer.

Halper Sadeh LLC Encourages Amgen Inc. Shareholders to Contact the Firm to Discuss Their Rights

Topics Economy Government Intellectual Property

October 22, 2025

From Halper Sadeh LLC

Via Business Wire

Price Over Earnings Overview: Amgen ↗

October 17, 2025

Via Benzinga

P/E Ratio Insights for Amgen ↗

October 03, 2025

Via Benzinga

Market Minute: Dow Soars, Apple Hits Record High as 20-Day Government Shutdown Fuels Gold Rally

October 20, 2025

The U.S. financial markets opened the week with a robust performance on October 20, 2025, as the Dow Jones Industrial Average (DJIA) extended its gains, and tech giant Apple Inc. (NASDAQ: AAPL) reached...

Although Amgen (currently trading at $299.86 per share) has gained 9.6% over the last six months, it has trailed the S&P 500’s 29.3% return during that period. This might have investors contemplating...

Topics Artificial Intelligence Economy Stocks

2 Reasons to Like AMGN and 1 to Stay Skeptical

October 20, 2025

United Therapeutics Forges Ahead with Share Repurchases, Not Dividends, Following July 2025 Volume Surge

Topics Stocks

October 17, 2025

In a financial landscape often fixated on consistent dividend payouts, United Therapeutics Corporation (NASDAQ: UTHR) stands out with a distinct capital allocation strategy. Contrary to market...

Trump's promise to cut cost of Novo Nordisk A/S drug Ozempic from $1,300 to $150 shakes GLP-1 gold rush, with potential impact on Eli Lilly and Pfizer.

Topics Retirement

Novo Vs. Lilly Vs. Pfizer: Who Wins If Trump Slashes The Price Of Weight Loss Drugs? ↗

October 17, 2025

Via Benzinga

Topics Government

Marjorie Taylor Greene, Cathie Wood Snap Up The Same 13 Stocks — Here's the Unlikely Portfolio Crossover ↗

October 16, 2025

A look at the stock owned by both Ark Funds and Congresswoman Marjorie Taylor Greene.

Via Benzinga

Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity ↗

October 16, 2025

William Blair assigns Climb Bio an Outperform rating, projecting peak sales of $1.9 billion and long-term growth for its therapy pipeline.

Via Benzinga

Dow Jones Stumbles with Fractional Dip, Signaling Cautious Market Sentiment Amidst Global Headwinds

October 15, 2025

New York, NY – October 15, 2025 – The Dow Jones Industrial Average (DJIA) experienced a fractional dip today, reflecting a palpable sense of caution pervading market sentiment. While other major...

Looking back on therapeutics stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Amgen (NASDAQ:AMGN) and its peers.

Topics Artificial Intelligence Economy Government

Reflecting On Therapeutics Stocks’ Q2 Earnings: Amgen (NASDAQ:AMGN)

October 12, 2025

Trump to announce new deal with AstraZeneca to lower prescription drug costs for Americans using most-favored-nation pricing model.

Topics Artificial Intelligence

Trump Plans AstraZeneca Deal To Cut Drug Prices For Low-Income Americans ↗

October 10, 2025

Via Benzinga

Topics Government

Trump Administration Engages Pharmacies, GoodRx For TrumpRx Launch ↗

October 09, 2025

Pharmacies and GoodRx are in talks to join TrumpRx, a new drug pricing site aiming to lower prescription costs for U.S. consumers.

Via Benzinga

Topics Government

10 Health Care Stocks Whale Activity In Today's Session ↗

October 08, 2025

Via Benzinga

2 S&P 500 Stocks to Target This Week and 1 Facing Challenges

October 08, 2025

The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some...

Topics Stocks

Martin Capital Buys Into Portland General Electric’s Defensive Power Play ↗

October 07, 2025

Amgen To Offer Cholesterol Drug At 60% Discount As Trump Administration's Call To Lower Drug Prices ↗

Topics Energy Regulatory Compliance

October 06, 2025

Amgen launches AmgenNow, offering Repatha at $239 per month, expanding direct access for U.S. patients with no insurer restrictions.

Via Benzinga

Topics Government

Martin Capital Dumps $3.0 Million Worth of LyondellBasell Industries Stock ↗

October 06, 2025

Martin Capital Liquidates its Diageo Position: What That Means for the Alcoholic Beverages Titan ↗

Topics Energy

October 06, 2025

Martin Capital Exits $5.8 Million Comcast Stake as Broadband Challenges Persist ↗

October 06, 2025

Martin Capital Sells $3.6 Million in JPMorgan Stock — What to Know Ahead of Q3 Earnings ↗

October 06, 2025

Patients can purchase Repatha at a discount through Amgen’s direct-to-patient program, AmgenNow.

Amgen To Sell Cholesterol Drug For Approximately 60% Discount ↗

October 06, 2025

Via Stocktwits

Topics Government

4 Reasons to Buy Amgen Stock Right Now ↗

October 04, 2025

For those with a sufficiently long investment horizon, the stock looks attractive.

S&P500, Nasdaq100, Dow Jones, and Russell 2000 all hit record highs as investors focus on corporate optimism, monetary easing and AI tech.

Topics Intellectual Property

Wall Street Hits Record Highs As Rate Cut Bets Offset Shutdown: This Week In Markets ↗

October 03, 2025

Via Benzinga

Topics Artificial Intelligence Stocks

FDA Greenlights Jazz and Roche's Zepzelca-Tecentriq for ES-SCLC Maintenance, Reshaping Lung Cancer Treatment Landscape

October 03, 2025

In a pivotal moment for oncology, the U.S. Food and Drug Administration (FDA) on October 2, 2025, granted approval for the innovative combination of Jazz Pharmaceuticals' (NASDAQ: JAZZ) Zepzelca...

U.S. Jobs Report Stalled Amidst Federal Shutdown: A Critical Information Vacuum for Markets and Policymakers

October 02, 2025

Washington D.C., October 2, 2025 – As a federal government shutdown extends into its second day, the highly anticipated U.S. Jobs Report, typically released on the first Friday of each month, has been...

On October 2, 2025, the Healthcare sector emerged as a beacon of stability and growth within the S&P 500, delivering a robust positive performance that significantly contributed to the broader market's...

Topics Bonds Economy

Healthcare Sector Shines Amidst Market Turbulence, Bolstering S&P 500 Resilience

October 02, 2025